天津泰达生物医学工程股份有限公司（08189）于2026年2月2日披露2026年1月股份变动月报表。公告显示，截至2026年1月31日，公司注册股本总额213,390,000人民币，较上月保持不变。
本月公司普通股分为H股与内资股两类。H股已发行股份数1,436,400,000股，内资股已发行股份数697,500,000股，二者合计面值分别为143,640,000人民币和69,750,000人民币，期内均未出现增发、购回或注销记录；不存在股份期权或其他权证的行使、失效与其他变化。
公司表示已遵守香港联交所《上市规则》及相关法律法规，确认本月所有与股份相关的事宜均获得董事会正式批准。截至本月末，股本结构保持稳定，无新增或回购活动。该公告由公司董事孙莉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.